Healthcare Providers and Services
Company Overview of Ambry Genetics Corp.
Ambry Genetics Corp. provides clinical diagnostics testing services for genetic diseases. It offers gene sequence analysis for cystic fibrosis; and customizable sequencing, genotyping, and microarray services. The company also provides clinical resources that support ongoing clinician education and sharing of data to promote scientific discoveries that help in improving patient management and care. It serves physicians, genetic counselors, and patients. Ambry Genetics Corp. was founded in 1999 and is based in Aliso Viejo, California.
Aliso Viejo, CA 92656
Founded in 1999
Key Executives for Ambry Genetics Corp.
Chief Executive Officer, Interim Chief Operating Officer and Interim Chief Scientific Officer
Founder, Chairman of the Board of Directors and President
Compensation as of Fiscal Year 2016.
Ambry Genetics Corp. Key Developments
Ambry Genetics Launches Comprehensive Multi-Gene Test for Hereditary Prostate Cancer
Sep 28 16
Ambry Genetics announced that it has launched ProstateNext, a new 14-gene panel for hereditary prostate cancer. Ambry will feature it at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference taking place September 28-October 1 in Seattle, WA. This also coincides with Prostate Cancer Awareness Month and follows a recent New England Journal of Medicine (NEJM) article demonstrating a higher frequency of germline mutations in men with metastatic prostate cancer. Prostate cancer is the second most common cancer among men in the U.S., representing 10.7% of all new cancer cases in the country. The median age at diagnosis for these men is 66 years. Due to available screening and treatment, prostate cancer in general has excellent survival rates, but death rates are higher in certain men, including those with advanced stage cancer (such as metastatic cancer). Several factors place a man at increased risk for prostate cancer, and these can include family history and germline mutations. Hereditary prostate cancer, the type caused by germline mutations traveling through a family, is believed to account for 5-10% of all prostate cancer (although this estimate is being refined with ongoing research). A germline mutation found in a man with prostate cancer can open the door to individualized prostate cancer treatment and/or screening for it and related cancers.
Ambry Genetics Announces Executive Changes
Mar 24 16
Ambry Genetics announced that Charles Dunlop, current CEO, will assume the role of Chairman of the Board of Directors and President. Aaron Elliott, PhD, current Chief Operating Officer and Chief Scientific Officer, will be appointed Chief Executive Officer. Dunlop will remain involved in the strategic direction of the company. He will also take a very active role in AmbryShare, which Ambry launched on March 8, 2016. Prior to joining Ambry in 2008 as a research and development scientist, Dr. Elliott worked at Novartis developing genomic strategies to profile cancer stem cells. He has held numerous roles of executive responsibility at Ambry and has been integral in guiding the company through extreme periods of growth.
Ambry Genetics Announces Newly Published Data on Hereditary Ovarian Cancer and Multi-Gene Panels
Feb 6 15
Ambry Genetics announced newly published data on hereditary cancer multi-gene panels, in Gynecologic Oncology. Published in collaboration with physicians at the University of Arizona, Hereditary Predisposition to Ovarian Cancer, Looking Beyond BRCA1/BRCA2, highlights important data regarding the role of multi-gene panels in diagnosing hereditary breast and ovarian cancer. This study analyzed data from 911 BRCA1/2-negative women with a history of breast and/or ovarian cancer who underwent testing with OvaNext, a multi-gene panel which currently includes 23 genes associated with hereditary breast, ovarian, and other cancers. Among the key findings, the authors identified an overall mutation rate of 7.4%, doubling the diagnostic yield compared to the expected mutation rate of 5-10% from BRCA1/2 mutation testing alone in similar cohorts. This article presents early data regarding moderate penetrance hereditary breast and ovarian cancer genes in a breast and ovarian cancer cohort. Among the ovarian cancer-only cohort, 26% of the mutations identified were in BRIP1 and 19% were in MSH6. Conversely, in the breast cancer-only cohort, the greater percentage of mutations were in CHEK2, ATM, and TP53 (34%, 11%, and 11%, respectively), with only 4% of mutations in BRIP1 inbreast cancer-only probands. Additionally, data presented in this article demonstrate that testing guidelines for known syndromes, such as Lynch syndrome, are not sufficient to detect all carriers of mutations predisposing to known hereditary cancer syndromes among cohort of patients, providing additional support for multi-gene panel based testing as opposed to phenotype-driven single gene testing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|